Amedisys Inc (NASDAQ:AMED) fell 7.3% on Monday . The stock traded as low as $48.48 and last traded at $48.91. 585,777 shares changed hands during trading, an increase of 48% from the average session volume of 395,765 shares. The stock had previously closed at $52.75.

Several brokerages recently weighed in on AMED. Mizuho cut Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a report on Wednesday, July 26th. BidaskClub cut Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 12th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $60.00 target price on shares of Amedisys in a report on Friday, September 15th. Bank of America Corporation began coverage on Amedisys in a report on Monday, August 21st. They set a “neutral” rating and a $55.00 target price for the company. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $60.00 target price on shares of Amedisys in a report on Monday. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Amedisys currently has a consensus rating of “Hold” and a consensus price target of $55.90.

The company’s 50-day moving average price is $51.97 and its 200-day moving average price is $55.24. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of 40.83 and a beta of 0.87.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The business had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. During the same quarter in the previous year, the business earned $0.42 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities research analysts forecast that Amedisys Inc will post $2.21 earnings per share for the current fiscal year.

In other Amedisys news, Director Bruce D. Perkins bought 2,000 shares of the company’s stock in a transaction on Thursday, August 3rd. The stock was acquired at an average price of $46.60 per share, for a total transaction of $93,200.00. Following the completion of the transaction, the director now directly owns 15,825 shares of the company’s stock, valued at $737,445. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider David B. Pearce sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total value of $50,000.00. Following the transaction, the insider now owns 10,488 shares of the company’s stock, valued at approximately $524,400. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the business. Riverhead Capital Management LLC boosted its position in shares of Amedisys by 75.5% during the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after buying an additional 831 shares during the period. Federated Investors Inc. PA boosted its position in shares of Amedisys by 2.3% during the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after buying an additional 44 shares during the period. Ameritas Investment Partners Inc. purchased a new position in shares of Amedisys during the first quarter valued at approximately $123,000. CIBC Asset Management Inc purchased a new position in shares of Amedisys during the second quarter valued at approximately $230,000. Finally, SG Americas Securities LLC boosted its position in shares of Amedisys by 48.7% during the second quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock valued at $235,000 after buying an additional 1,226 shares during the period. Institutional investors and hedge funds own 96.55% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/11/amedisys-inc-amed-stock-price-down-7-3.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.